Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Mar. 31, 2014 | 13-May-14 | |
Document and Entity Information [Abstract] | ' | ' |
Entity Registrant Name | 'NATURAL ALTERNATIVES INTERNATIONAL INC | ' |
Document Type | '10-Q | ' |
Current Fiscal Year End Date | '--06-30 | ' |
Entity Common Stock, Shares Outstanding | ' | 6,997,754 |
Amendment Flag | 'false | ' |
Entity Central Index Key | '0000787253 | ' |
Entity Current Reporting Status | 'Yes | ' |
Entity Voluntary Filers | 'No | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Well-known Seasoned Issuer | 'No | ' |
Document Period End Date | 31-Mar-14 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $15,217 | $16,697 |
Accounts receivable - less allowance for doubtful accounts of $140 at March 31, 2014 and $144 at June 30, 2013 | 6,843 | 6,605 |
Inventories, net | 14,367 | 10,035 |
Deferred income taxes | 567 | 609 |
Income tax receivable | 389 | 160 |
Prepaid expenses and other current assets | 1,253 | 1,217 |
Total current assets | 38,636 | 35,323 |
Property and equipment, net | 8,875 | 9,205 |
Deferred income taxes | 1,116 | 1,527 |
Other noncurrent assets, net | 902 | 585 |
Total assets | 49,529 | 46,640 |
Current liabilities: | ' | ' |
Accounts payable | 4,658 | 3,539 |
Accrued liabilities | 2,102 | 1,130 |
Accrued compensation and employee benefits | 961 | 807 |
Income taxes payable | 462 | 466 |
Total current liabilities | 8,183 | 5,942 |
Other noncurrent liabilities, net | 171 | 134 |
Deferred rent | ' | 225 |
Total liabilities | 8,354 | 6,301 |
Stockholders’ equity: | ' | ' |
Preferred stock; $.01 par value; 500,000 shares authorized; none issued or outstanding | 0 | 0 |
Common stock; $.01 par value; 20,000,000 shares authorized; issued and outstanding (net of treasury shares) 6,997,754 at March 31, 2014 and 6,914,555 at June 30, 2013 | 74 | 73 |
Additional paid-in capital | 19,809 | 19,662 |
Accumulated other comprehensive loss | -586 | -430 |
Retained earnings | 24,571 | 23,667 |
Treasury stock, at cost, 515,923 shares at March 31, 2014 and 494,122 at June 30, 2013 | -2,693 | -2,633 |
Total stockholders’ equity | 41,175 | 40,339 |
Total liabilities and stockholders’ equity | $49,529 | $46,640 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
In Thousands, except Share data, unless otherwise specified | ||
Accounts receivable, allowance for doubtful accounts (in Dollars) | $140 | $144 |
Preferred stock par value (in Dollars per share) | $0.01 | $0.01 |
Preferred stock, shares authorized | 500,000 | 500,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in Dollars per share) | $0.01 | $0.01 |
Common stock, shares authorized | 20,000,000 | 20,000,000 |
Common stock, issued | 6,997,754 | 6,914,555 |
Common stock, outstanding | 6,997,754 | 6,914,555 |
Treasury stock, shares | 515,923 | 494,122 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 |
Net sales | $19,127 | $15,835 | $52,757 | $45,981 |
Cost of goods sold | 15,685 | 12,972 | 44,056 | 37,357 |
Gross profit | 3,442 | 2,863 | 8,701 | 8,624 |
Selling, general & administrative expenses | 2,274 | 2,294 | 7,179 | 7,299 |
Income from operations | 1,168 | 569 | 1,522 | 1,325 |
Other (expense) income: | ' | ' | ' | ' |
Interest income | 7 | 14 | 28 | 35 |
Interest expense | -3 | -5 | -8 | -16 |
Foreign exchange loss | -25 | -57 | -15 | -72 |
Other, net | -94 | ' | -87 | ' |
-115 | -48 | -82 | -53 | |
Income before income taxes | 1,053 | 521 | 1,440 | 1,272 |
Provision for income taxes | 431 | 343 | 536 | 295 |
Net income | 622 | 178 | 904 | 977 |
Unrealized gain (loss) resulting from change in fair value of derivative instruments, net of tax | 83 | 124 | -120 | -412 |
Change in minimum pension liability, net of tax | -36 | ' | -36 | ' |
Comprehensive income | $669 | $302 | $748 | $565 |
Net income per common share: | ' | ' | ' | ' |
Basic (in Dollars per share) | $0.09 | $0.03 | $0.13 | $0.14 |
Diluted (in Dollars per share) | $0.09 | $0.03 | $0.13 | $0.14 |
Weighted average common shares outstanding: | ' | ' | ' | ' |
Basic (in Shares) | 6,819,071 | 6,841,163 | 6,817,643 | 6,883,304 |
Diluted (in Shares) | 6,842,951 | 6,843,897 | 6,845,765 | 6,891,023 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 9 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Cash flows from operating activities | ' | ' |
Net income | $904,000 | $977,000 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Decrease of uncollectible accounts receivable | -15,000 | -101,000 |
Depreciation and amortization | 2,325,000 | 2,275,000 |
Deferred income taxes | 453,000 | ' |
Non-cash compensation | 148,000 | 135,000 |
Pension expense | 37,000 | 7,000 |
Gain on disposal of assets | -27,000 | -22,000 |
Changes in operating assets and liabilities: | ' | ' |
Accounts receivable | -223,000 | 2,737,000 |
Inventories, net | -4,332,000 | -1,725,000 |
Other assets | -401,000 | 110,000 |
Accounts payable and accrued liabilities | 1,748,000 | -1,934,000 |
Income taxes | -200,000 | 59,000 |
Accrued compensation and employee benefits | 154,000 | -451,000 |
Net cash provided by operating activities | 571,000 | 2,067,000 |
Cash flows from investing activities | ' | ' |
Capital expenditures | -2,198,000 | -1,379,000 |
Proceeds from the sale of property & equipment | 207,000 | 31,000 |
Net cash used by investing activities | -1,991,000 | -1,348,000 |
Cash flows from financing activities | ' | ' |
Issuance of common stock | ' | 37,000 |
Repurchase of common stock | -60,000 | -596,000 |
Net cash used by financing activities | -60,000 | -559,000 |
Net (decrease) increase in cash and cash equivalents | -1,480,000 | 160,000 |
Cash and cash equivalents at beginning of period | 16,697,000 | 14,478,000 |
Cash and cash equivalents at end of period | 15,217,000 | 14,638,000 |
Cash paid during the period for: | ' | ' |
Interest | 13,000 | 13,000 |
Taxes | 305,000 | 255,000 |
Disclosure of non-cash activities: | ' | ' |
Change in unrealized loss resulting from change in fair value of derivative instruments, net of tax | 120,000 | 412,000 |
Fixed assets in accounts payable | $5,000 | ' |
Note_A_Basis_of_Presentation_a
Note A - Basis of Presentation and Summary of Significant Accounting Policies | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | ' | ||||||||||||||||
A. Basis of Presentation and Summary of Significant Accounting Policies | |||||||||||||||||
Basis of Presentation | |||||||||||||||||
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and applicable rules and regulations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. In management’s opinion, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows have been included and are of a normal, recurring nature. The results of operations for the three and nine months ended March 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future periods. | |||||||||||||||||
You should read the financial statements and these notes, which are an integral part of the financial statements, together with our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2013 (“2013 Annual Report”). The accounting policies used to prepare the financial statements included in this report are the same as those described in the notes to the consolidated financial statements in our 2013 Annual Report unless otherwise noted below. | |||||||||||||||||
Reclassifications | |||||||||||||||||
Certain items previously reported in our prior years’ condensed consolidated financial statements have been reclassified to conform with current year presentation. The reclassification relates to the classification of certain operating expenses from our NAIE operations previously classified as cost of goods sold, which are now being classified as part of selling, general & administrative expenses. This reclassification was made to reflect the change in operational activity of NAIE, which has historically been primarily a manufacturing specific operation but is now transitioning to perform additional selling and administrative functions. The reclassified amount relating to the three months ended March 31, 2013 totaled $85,000. The reclassified amount relating to the nine months ended March 31, 2013 totaled $343,000. This reclassification had no effect on previously reported total assets, stockholders’ equity, or net income. | |||||||||||||||||
Recent Accounting Pronouncements | |||||||||||||||||
In July 2013, the Financial Accounting Standards Board (the “FASB”) issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This amendment to previous income tax guidance clarifies that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax benefit is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be netted with the deferred tax asset. These amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. We adopted Accounting Standard Update 2013-11 during our third quarter of fiscal 2014 and there was not significant impact to our consolidated financial statements as a result of our adoption of this amendment. | |||||||||||||||||
Net Income per Common Share | |||||||||||||||||
We compute net income per common share using the weighted average number of common shares outstanding during the period, and diluted net income per common share using the additional dilutive effect of all dilutive securities. The dilutive impact of stock options account for the additional weighted average shares of common stock outstanding for our diluted net income per common share computation. We calculated basic and diluted net income per common share as follows (in thousands, except share and per share data): | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
March 31, | March 31, | ||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||
Numerator | |||||||||||||||||
Net income | $ | 622 | $ | 178 | $ | 904 | $ | 977 | |||||||||
Denominator | |||||||||||||||||
Basic weighted average common shares outstanding | 6,819 | 6,841 | 6,818 | 6,883 | |||||||||||||
Dilutive effect of stock options | 24 | 3 | 28 | 8 | |||||||||||||
Diluted weighted average common shares outstanding | 6,843 | 6,844 | 6,846 | 6,891 | |||||||||||||
Basic net income per common share | $ | 0.09 | $ | 0.03 | $ | 0.13 | $ | 0.14 | |||||||||
Diluted net income per common share | $ | 0.09 | $ | 0.03 | $ | 0.13 | $ | 0.14 | |||||||||
Shares related to stock options representing the right to acquire 280,019 shares of common stock for the three months ended March 31, 2014, and 303,929 shares for the nine months ended March 31, 2014, were excluded from the calculation of diluted net income per common share, as the effect of their inclusion would have been anti-dilutive. | |||||||||||||||||
Shares related to stock options representing the right to acquire 390,000 shares of common stock for the three months ended March 31, 2013, and 457,800 shares for the nine months ended March 31, 2013, were excluded from the calculation of diluted net income per common share, as the effect of their inclusion would have been anti-dilutive. | |||||||||||||||||
Revenue Recognition | |||||||||||||||||
To recognize revenue, four basic criteria must be met: 1) there is evidence that an arrangement exists; 2) delivery has occurred; 3) the fee is fixed or determinable; and 4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the seller’s price to the buyer is substantially fixed or determinable at the date of sale; (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product; (3) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product; (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller; (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and (6) the amount of future returns can be reasonably estimated. We recognize revenue upon determination that all criteria for revenue recognition have been met. The criteria are usually met at the time title passes to the customer, which usually occurs upon shipment. Revenue from shipments where title passes upon delivery is deferred until the shipment has been delivered. | |||||||||||||||||
We record reductions to gross revenue for estimated returns of private label contract manufacturing products and branded products. The estimated returns are based on the trailing six months of private label contract manufacturing gross sales and our historical experience for both private label contract manufacturing and branded product returns. However, the estimate for product returns does not reflect the impact of a potential large product recall resulting from product nonconformance or other factors as such events are not predictable nor is the related economic impact estimable. | |||||||||||||||||
We followed the provisions of ASU No. 2009-13 for all multiple element agreements. Under this guidance, the delivered item(s) has value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. | |||||||||||||||||
A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that a deliverable has standalone value from the undelivered items, the deliverable is identified as a separate unit of accounting and the amounts allocated to the deliverable are recognized upon the delivery of the deliverable, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the deliverable through the relative selling price allocation exceed the upfront fee, the amount recognized upon the delivery of the deliverable is limited to the upfront fee received. If facts and circumstances dictate that the deliverable does not have standalone value, the transaction price, including any upfront fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered and accepted. | |||||||||||||||||
In addition, we enter into arrangements that provide for milestone payments upon contractually stated events. Under the Milestone Method, we recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: 1) The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, 2) The consideration relates solely to past performance, and 3) The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to us. | |||||||||||||||||
We currently own certain U.S. patents, and each patent’s corresponding foreign patent applications. All of these patents and patent rights relate to the ingredient known as beta-alanine marketed and sold under the CarnoSyn® trade name. We have sold this ingredient to a customer and, since March 2009, we have had an agreement with Compound Solutions, Inc. (CSI) under which we have agreed to grant a license of certain of our patent rights to customers of CSI who purchase beta-alanine from CSI. Before October 1, 2011, we received a fee from CSI that varied based on the amount of net sales of beta-alanine sold by CSI less CSI’s costs and other agreed upon expenses. As of October 1, 2011, we receive a fee from CSI that varies based on the quantity of beta-alanine sold by CSI and the source of such beta-alanine. | |||||||||||||||||
In June 2011, we entered into a license and supply agreement (Agreement) with Abbott Laboratories (Abbott) under which we agreed to grant an exclusive license to Abbott for the use of beta-alanine in certain medical foods and medical nutritionals. Under the terms of the agreement, Abbott paid an initial license fee of $300,000, an additional fee of $300,000 in January 2012, and upon achievement of certain milestones, an additional license fee of $150,000 was paid on October 3, 2012. The license and supply agreement provided Abbott with the right to terminate the agreement at any time up to March 31, 2012, at which time, if not terminated, Abbott was required to pay $4.3 million payable over six annual payments with the initial installment payment of $708,334 due March 31, 2012. We have determined that each of the milestone payments meets the definition of a milestone in accordance with the milestone method of revenue recognition. | |||||||||||||||||
In February 2012 and June 2012, we amended the Agreement and extended Abbott’s termination rights initially through July 31, 2012 and then further through October 31, 2012 in exchange for two payments of $354,167 each by Abbott to NAI. Abbott made the first payment on March 13, 2012 and the second payment on July 12, 2012. In October 2012, the Agreement was amended for a third time. Unless earlier terminated by Abbott, the amendment requires Abbott to pay to NAI (i) upon earlier of achievement of certain milestones or December 1, 2012, additional license fees of $204,167; (ii) upon earlier of achievement of certain milestones or June 1, 2013, additional license fees of $204,167; (iii) upon earlier of achievement of certain milestones or July 1, 2013, additional license fees of $150,000; (iv) upon earlier of achievement of certain milestones or December 1, 2013, additional license fees of $150,000; and (v) approximately $2.8 million payable over four annual payments beginning on March 31, 2014. The payment noted in (i) was collected in December 2012, the payment noted in (ii) was collected in May 2013, the payment noted in (iii) was collected in July 2013 and the payment noted in (iv) was collected in January 2014. | |||||||||||||||||
Effective November 27, 2013, citing further time and cost required to bring its anticipated product to market, Abbott exercised its right to terminate the Agreement. | |||||||||||||||||
We recorded royalty and licensing income as a component of revenue in the amount of $1.1 million during the three months ended March 31, 2014 and $3.8 million during the nine months ended March 31, 2014. We recorded royalty and licensing income as a component of revenue in the amount of $1.0 million during the three months ended March 31, 2013 and $3.2 million during the nine months ended March 31, 2013. These royalty and licensing income amounts resulted in royalty expense paid to the original patent holders from whom NAI acquired its patents and patent rights. We recognized royalty expense as a component of cost of goods sold in the amount of $143,000 during the three months ended March 31, 2014 and $523,000 during the nine months ended March 31, 2014. We recognized royalty expense as a component of cost of goods sold in the amount of $133,000 during the three months ended March 31, 2013 and $426,000 during the nine months ended March 31, 2013. | |||||||||||||||||
Stock-Based Compensation | |||||||||||||||||
We have an omnibus incentive plan that was approved by our Board of Directors effective as of October 15, 2009 and approved by our stockholders at the Annual Meeting of Stockholders held on November 30, 2009. Under the plan, we may grant nonqualified and incentive stock options and other stock-based awards to employees, non-employee directors and consultants. Our prior equity incentive plan was terminated effective as of November 30, 2009. | |||||||||||||||||
We estimate the fair value of stock option awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions. Black-Scholes uses assumptions related to volatility, the risk-free interest rate, the dividend yield (which we assume to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities used in the model are based mainly on the historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect in the period of grant. The expected life of stock option grants is derived from historical experience. | |||||||||||||||||
During fiscal 2013 we granted a total of 98,000 restricted stock shares to the members of our Board of Directors and certain key members of our management team pursuant to our 2009 Omnibus Incentive plan. Each restricted share will vest over three years and these shares cannot be sold or otherwise transferred and the rights to receive dividends, if declared by our Board of Directors, are forfeitable until the shares become vested. During the three months ended September 30, 2013, 10,000 of these shares were forfeited due to the termination of employment of one of the grantees. On March 7, 2014 we granted 105,000 restricted stock shares to the members of our Board of Directors and certain key members of our management team pursuant to our 2009 Omnibus Incentive plan. These restricted stock grants will vest over three years and cannot be sold or otherwise transferred and the rights to receive dividends, if declared by our Board of Directors, are forfeitable until the shares become vested. | |||||||||||||||||
Our net income included stock based compensation expense of approximately $46,000 for the three months ended March 31, 2014 and approximately $148,000 for the nine months ended March 31, 2014. Our net income included stock based compensation expense of approximately $52,000 for the three months ended March 31, 2013 and approximately $135,000 for the nine months ended March 31, 2013. | |||||||||||||||||
Fair Value of Financial Instruments | |||||||||||||||||
Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We use a three-level hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available under the circumstances. | |||||||||||||||||
The fair value hierarchy is broken down into three levels based on the source of inputs. In general, fair values determined by Level 1 inputs use quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. We classify cash, cash equivalents, and marketable securities balances as Level 1 assets. Fair values determined by Level 2 inputs are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable or can be corroborated, either directly or indirectly by observable market data. Level 3 inputs are unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. These include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. | |||||||||||||||||
As of March 31, 2014 and June 30, 2013, we did not have any financial assets or liabilities classified as Level 1. We classify derivative forward exchange contracts as Level 2 assets. The fair value of our forward exchange contracts as of March 31, 2014 was a net liability of $204,000. The fair value of our forward exchange contracts as of June 30, 2013 was an asset of $95,000. As of March 31, 2014 and June 30, 2013, we did not have any financial assets or liabilities classified as Level 3. We did not transfer any assets between Levels 1, 2 and 3 during fiscal 2013 or the nine month period ended March 31, 2014. |
Note_B_Inventories
Note B - Inventories | 9 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventory Disclosure [Text Block] | ' | ||||||||
B. Inventories | |||||||||
Inventories, net consisted of the following (in thousands): | |||||||||
March 31, | June 30, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 10,214 | $ | 6,516 | |||||
Work in progress | 3,376 | 1,576 | |||||||
Finished goods | 1,582 | 2,358 | |||||||
Reserves | (805 | ) | (415 | ) | |||||
$ | 14,367 | $ | 10,035 | ||||||
Note_C_Property_and_Equipment
Note C - Property and Equipment | 9 Months Ended | ||||||||||||
Mar. 31, 2014 | |||||||||||||
Property, Plant and Equipment [Abstract] | ' | ||||||||||||
Property, Plant and Equipment Disclosure [Text Block] | ' | ||||||||||||
C. Property and Equipment | |||||||||||||
Property and equipment consisted of the following (dollars in thousands): | |||||||||||||
Depreciable | March 31, | June 30, | |||||||||||
Life In Years | 2014 | 2013 | |||||||||||
Land | N/A | $ | 393 | $ | 393 | ||||||||
Building and building improvements | 7 – 39 | 2,793 | 2,793 | ||||||||||
Machinery and equipment | 3 – 12 | 26,523 | 26,141 | ||||||||||
Office equipment and furniture | 3 – 5 | 3,206 | 3,030 | ||||||||||
Vehicles | 3 | 209 | 136 | ||||||||||
Leasehold improvements | 1 – 15 | 10,921 | 10,771 | ||||||||||
Total property and equipment | 44,045 | 43,264 | |||||||||||
Less: accumulated depreciation and amortization | (35,170 | ) | (34,059 | ) | |||||||||
Property and equipment, net | $ | 8,875 | $ | 9,205 | |||||||||
Note_D_Other_Comprehensive_Los
Note D - Other Comprehensive (Loss) Income | 9 Months Ended | ||||||||||||
Mar. 31, 2014 | |||||||||||||
Disclosure Text Block [Abstract] | ' | ||||||||||||
Comprehensive Income (Loss) Note [Text Block] | ' | ||||||||||||
D. Other comprehensive (loss) income | |||||||||||||
Three Months Ended March 31, 2014 | |||||||||||||
Defined Benefit | Unrealized | Total | |||||||||||
Pension Plan | Losses on Cash | ||||||||||||
Flow Hedges | |||||||||||||
Balance as of December 31, 2013 | $ | (482 | ) | $ | (151 | ) | $ | (633 | ) | ||||
Other comprehensive loss before reclassifications | — | 35 | 35 | ||||||||||
Amounts reclassified from OCI | — | 112 | 112 | ||||||||||
Tax effect of OCI activity | (36 | ) | (64 | ) | (100 | ) | |||||||
Other comprehensive loss | (36 | ) | 83 | 47 | |||||||||
Balance as of March 31, 2014 | $ | (518 | ) | $ | (68 | ) | $ | (586 | ) | ||||
Nine Months Ended March 31, 2014 | |||||||||||||
Defined Benefit | Unrealized | Total | |||||||||||
Pension Plan | Losses on Cash | ||||||||||||
Flow Hedges | |||||||||||||
Balance as of June 30, 2013 | $ | (482 | ) | $ | 52 | $ | (430 | ) | |||||
Other comprehensive loss before reclassifications | — | (533 | ) | (533 | ) | ||||||||
Amounts reclassified from OCI | — | 343 | 343 | ||||||||||
Tax effect of OCI activity | (36 | ) | 70 | 34 | |||||||||
Other comprehensive loss | (36 | ) | (120 | ) | (156 | ) | |||||||
Balance as of March 31, 2014 | $ | (518 | ) | $ | (68 | ) | $ | (586 | ) | ||||
During the three months ended March 31, 2014, the amounts reclassified from OCI were comprised of $116,000 of losses reclassified to net revenues and $4,000 related to the amortization of forward points reclassified to other income. During the nine months ended March 31, 2014, the amounts reclassified from OCI were comprised of $361,000 of losses reclassified to net revenues and $18,000 related to the amortization of forward points reclassified to other income. |
Note_E_Debt
Note E - Debt | 9 Months Ended |
Mar. 31, 2014 | |
Debt Disclosure [Abstract] | ' |
Debt Disclosure [Text Block] | ' |
E. Debt | |
On December 16, 2010, we executed a Credit Agreement (“Credit Agreement”) with Wells Fargo Bank, National Association. This Credit Agreement replaced our previous credit facility and provides us with a line of credit of up to $5.0 million. The line of credit may be used to finance working capital requirements. In consideration for granting the line of credit and each subsequent extension amendment, we pay an annual commitment fee of $12,500. There are no amounts currently drawn under the line of credit. | |
Under the terms of the Credit Agreement, borrowings are subject to eligibility requirements including maintaining (i) net income after taxes of not less than $750,000 on a trailing four quarter basis as of the end of each calendar quarter beginning with the four quarter period ended December 31, 2010; and (ii) a ratio of total liabilities to tangible net worth of not greater than 1.25 to 1.0 at any time. Any amounts outstanding under the line of credit will bear interest at a fixed or fluctuating interest rate as elected by NAI from time to time; provided, however, that if the outstanding principal amount is less than $100,000 such amount shall bear interest at the then applicable fluctuating rate of interest. If elected, the fluctuating rate per annum would be equal to 2.75% above the daily one month LIBOR rate as in effect from time to time. If a fixed rate is elected, it would equal a per annum rate of 2.50% above the LIBOR rate in effect on the first day of the applicable fixed rate term. Any amounts outstanding under the line of credit must be paid in full on or before November 1, 2015; provided, however, that we must maintain a zero balance on advances under the line of credit for a period of at least 30 consecutive days during each fiscal year. Amounts outstanding that are subject to a fluctuating interest rate may be prepaid at any time without penalty. Amounts outstanding that are subject to a fixed interest rate may be prepaid at any time in minimum amounts of $100,000, subject to a prepayment fee equal to the sum of the discounted monthly differences for each month from the month of prepayment through the month in which the then applicable fixed rate term matures. | |
Our obligations under the Credit Agreement are secured by our accounts receivable and other rights to payment, general intangibles, inventory, equipment and fixtures. We also have a foreign exchange facility with Wells Fargo in effect until November 1, 2014, and with Bank of America, N.A. in effect until August 15, 2015. | |
On March 31, 2014, we were in compliance with all of the financial and other covenants required under the Credit Agreement. | |
On September 22, 2006, NAIE, our wholly owned subsidiary, entered into a credit facility with Credit Suisse to provide NAIE with a credit line of up to CHF 1.3 million, or approximately $1.5 million, which was the initial maximum aggregate amount that could be outstanding at any one time under the credit facility. This maximum amount is reduced annually by CHF 160,000, or approximately $180,000. On February 19, 2007, NAIE amended its credit facility to provide that the maximum aggregate amount that may be outstanding under the facility cannot be reduced below CHF 500,000, or approximately $564,000. As of March 31, 2014, there was no outstanding balance under this credit facility. | |
Under its credit facility, NAIE may draw amounts either as current account loan credits to its current or future bank accounts or as fixed loans with a maximum term of 24 months. Current account loans will bear interest at the rate of 5% per annum. Fixed loans will bear interest at a rate determined by the parties based on current market conditions and must be repaid pursuant to a repayment schedule established by the parties at the time of the loan. If a fixed loan is repaid early at NAIE’s election or in connection with the termination of the credit facility, NAIE will be charged a pre-payment penalty equal to 0.1% of the principal amount of the fixed loan or CHF 1,000 (approximately $1,127), whichever is greater. The bank reserves the right to refuse individual requests for an advance under the credit facility, although its exercise of such right will not have the effect of terminating the credit facility as a whole. | |
We did not use our working capital line of credit nor did we have any long-term debt outstanding during the nine months ended March 31, 2014. As of March 31, 2014, we had $5.6 million available under our credit facilities. |
Note_F_Defined_Benefit_Pension
Note F - Defined Benefit Pension Plan | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | ' | ||||||||||||||||
Pension and Other Postretirement Benefits Disclosure [Text Block] | ' | ||||||||||||||||
F. Defined Benefit Pension Plan | |||||||||||||||||
We sponsor a defined benefit pension plan that provides retirement benefits to employees based generally on years of service and compensation during the last five years before retirement. Effective June 20, 1999, we adopted an amendment to freeze benefit accruals to the participants. We contribute an amount not less than the minimum funding requirements of the Employee Retirement Income Security Act of 1974 nor more than the maximum tax-deductible amount. | |||||||||||||||||
The components included in the net periodic expense for the periods ended March 31 were as follows (in thousands): | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
March 31, | March 31, | ||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||
Interest cost | $ | 22 | $ | 22 | $ | 66 | $ | 66 | |||||||||
Expected return on plan assets | (9 | ) | (3 | ) | (28 | ) | (8 | ) | |||||||||
Net periodic expense | $ | 13 | $ | 19 | $ | 38 | $ | 58 | |||||||||
Note_G_Economic_Dependency
Note G - Economic Dependency | 9 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||||||
Risks and Uncertainties [Abstract] | ' | ||||||||||||||||||||||||||||||||
Concentration Risk Disclosure [Text Block] | ' | ||||||||||||||||||||||||||||||||
G. Economic Dependency | |||||||||||||||||||||||||||||||||
We had substantial net sales to certain customers during the periods shown in the following table. The loss of any of these customers, or a significant decline in sales, or the growth rate of sales to these customers, or in their ability to make payments when due, could have a material adverse impact on our net sales and net income. Net sales to any one customer representing 10% or more of the respective period's total private label contract manufacturing net sales were as follows (dollars in thousands): | |||||||||||||||||||||||||||||||||
Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||||||||||
Net Sales by | % of Total | Net Sales by | % of Total | Net Sales by | % of Total | Net Sales by | % of Total | ||||||||||||||||||||||||||
Customer | Net Sales | Customer | Net Sales | Customer | Net Sales | Customer | Net Sales | ||||||||||||||||||||||||||
Customer 1 | $ | 6,321 | 36 | % | $ | 7,304 | 50 | % | $ | 16,849 | 35 | % | $ | 22,172 | 53 | % | |||||||||||||||||
Customer 2 | 2,823 | 16 | 2,455 | 17 | 8,484 | 18 | 7,072 | 17 | |||||||||||||||||||||||||
Customer 3 | 2,921 | 17 | 1,483 | 10 | 7,960 | 17 | (a) | (a) | |||||||||||||||||||||||||
$ | 12,065 | 69 | % | $ | 11,242 | 77 | % | $ | 33,293 | 70 | % | $ | 29,244 | 70 | % | ||||||||||||||||||
(a) | Sales were less than 10% of the respective period’s total private label contract manufacturing net sales. | ||||||||||||||||||||||||||||||||
We buy certain products, including beta-alanine, from a limited number of raw material suppliers. The loss of any of these suppliers could have a material adverse impact on our net sales and net income. Raw material purchases from any one supplier representing 10% or more of the respective period’s total raw material purchases were as follows (dollars in thousands): | |||||||||||||||||||||||||||||||||
Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||||||||||
Raw Material | % of Total | Raw Material | % of Total | Raw Material | % of Total | Raw Material | % of Total | ||||||||||||||||||||||||||
Purchases by | Raw | Purchases by | Raw | Purchases by | Raw | Purchases by | Raw | ||||||||||||||||||||||||||
Supplier | Material | Supplier | Material | Supplier | Material | Supplier | Material | ||||||||||||||||||||||||||
Purchases | Purchases | Purchases | Purchases | ||||||||||||||||||||||||||||||
Supplier 1 | (a) | (a) | $ | 829,000 | 14 | % | (a) | (a) | (a) | (a) | |||||||||||||||||||||||
(a) | (a) | $ | 829,000 | 14 | % | (a) | (a) | (a) | (a) | ||||||||||||||||||||||||
(a) Purchases were less than 10% of the respective period’s total raw material purchases. | |||||||||||||||||||||||||||||||||
Note_H_Segment_Information
Note H - Segment Information | 9 Months Ended | ||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||||||||||
Segment Reporting Disclosure [Text Block] | ' | ||||||||||||||||||||||||
H. Segment Information | |||||||||||||||||||||||||
Our business consists of three segments for financial reporting purposes. The three segments are identified as (i) private label contract manufacturing, which primarily relates to the provision of private label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, (ii) patent and trademark licensing, which primarily includes royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnosSyn® trade name and the sale of beta-alanine raw material, and (iii) branded products, which relates to the marketing and distribution of our branded nutritional supplements and consists primarily of the products sold under our Pathway to Healing® product line. | |||||||||||||||||||||||||
We evaluate performance based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before corporate allocations. Operating income for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to: human resources, corporate legal, finance, information technology, and other corporate level related expenses, which are not allocated to any segment. The accounting policies of our segments are the same as those described in Note A above and in the consolidated financial statements included in our 2013 Annual Report. | |||||||||||||||||||||||||
Our operating results by business segment were as follows (in thousands): | |||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||
Net Sales | |||||||||||||||||||||||||
Private label contract manufacturing | $ | 17,692 | $ | 14,505 | $ | 48,056 | $ | 41,773 | |||||||||||||||||
Patent and trademark licensing | 1,141 | 1,009 | 3,812 | 3,207 | |||||||||||||||||||||
Branded products | 294 | 321 | 889 | 1,001 | |||||||||||||||||||||
$ | 19,127 | $ | 15,835 | $ | 52,757 | $ | 45,981 | ||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||
Income from Operations | |||||||||||||||||||||||||
Private label contract manufacturing | $ | 1,717 | $ | 1,353 | $ | 3,434 | $ | 3,924 | |||||||||||||||||
Patent and trademark licensing | 570 | 337 | 1,500 | 654 | |||||||||||||||||||||
Branded products | 46 | 11 | 61 | 85 | |||||||||||||||||||||
Income from operations of reportable segments | 2,333 | 1,701 | 4,995 | 4,663 | |||||||||||||||||||||
Corporate expenses not allocated to segments | (1,165 | ) | (1,132 | ) | (3,473 | ) | (3,338 | ) | |||||||||||||||||
$ | 1,168 | $ | 569 | $ | 1,522 | $ | 1,325 | ||||||||||||||||||
March 31, | June 30, | ||||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||||
Total Assets | |||||||||||||||||||||||||
Private label contract manufacturing | $ | 48,180 | $ | 45,032 | |||||||||||||||||||||
Patent and trademark licensing | 1,141 | 1,388 | |||||||||||||||||||||||
Branded products | 208 | 220 | |||||||||||||||||||||||
$ | 49,529 | $ | 46,640 | ||||||||||||||||||||||
Our private label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Canada, Mexico, Australia and Asia. Our primary market outside the U.S. is Europe. Our patent and trademark licensing activities are primarily based in the U.S. and our branded products are only sold in the U.S. | |||||||||||||||||||||||||
Net sales by geographic region, based on the customers’ location, were as follows (in thousands): | |||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||
United States | $ | 8,992 | $ | 9,485 | $ | 26,695 | $ | 27,288 | |||||||||||||||||
Markets outside the United States | 10,135 | 6,350 | 26,062 | 18,693 | |||||||||||||||||||||
Total net sales | $ | 19,127 | $ | 15,835 | $ | 52,757 | $ | 45,981 | |||||||||||||||||
Products manufactured by NAIE accounted for approximately 61% of net sales in markets outside the U.S. for the three months ended March 31, 2014, and 73% for the three months ended March 31, 2013. NAIE accounted for 55% of net sales in markets outside the U.S. for the nine months ended March 31, 2014, and 72% for the nine months ended March 31, 2013. No products manufactured by NAIE were sold in the U.S. during the nine months ended March 31, 2014 and 2013. | |||||||||||||||||||||||||
Assets and capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands): | |||||||||||||||||||||||||
Long-Lived Assets | Total Assets | Capital Expenditures | |||||||||||||||||||||||
Nine Months Ended | |||||||||||||||||||||||||
March 31, | June 30, | March 31, | June 30, | March 31, | March 31, | ||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||
United States | $ | 6,588 | $ | 6,728 | $ | 34,376 | $ | 32,450 | $ | 1869 | $ | 635 | |||||||||||||
Europe | 2,287 | 2,477 | 15,153 | 14,190 | 329 | 719 | |||||||||||||||||||
$ | 8,875 | $ | 9,205 | $ | 49,529 | $ | 46,640 | $ | 2,198 | $ | 1,354 | ||||||||||||||
Note_I_Income_Taxes
Note I - Income Taxes | 9 Months Ended |
Mar. 31, 2014 | |
Income Tax Disclosure [Abstract] | ' |
Income Tax Disclosure [Text Block] | ' |
I. Income Taxes | |
The effective tax rate for the three months ended March 31, 2014 was an expense of 40.9% and the effective tax rate for the nine months ended March 31, 2014 was an expense of 37.2%. The rate differs from the U.S. federal statutory rate of 34% primarily due to the recognition of state income taxes partially offset by the favorable impact of foreign earnings taxed at less than the U.S. statutory rate and adjustments for discrete items that occurred during the three months ended March 31, 2014, as discussed below. The estimated state tax rate included in the effective tax rate has been adjusted for changes in the estimated California apportionment factor and estimates of income taxes in other states resulting from a state nexus study which was completed during the quarter. | |
To determine our quarterly provision for income taxes, we used an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions to which the Company is subject. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rate from quarter to quarter. For the three months ended March 31, 2014 these discrete items included (1) an expense to adjust the state deferred tax assets as a result of a change in the estimated state tax rate, (2) an expense to establish a valuation allowance on a portion of the deferred tax asset for the California net operating loss, (3) a net benefit of state taxes as a result of adjusting California apportionment and filing in other states for prior years, and (4) a true-up of the R&D credit claimed on the federal income tax return filed in the current quarter. We recognize interest and penalties related to uncertain tax positions, if any, as an income tax expense. | |
We record valuation allowances to reduce our deferred tax assets to an amount that we believe is more likely than not to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. During the three months ended March 31, 2014, as a result of changes in California apportionment rules and the state nexus study which was completed during the quarter, the Company determined that $193,000 of the deferred tax asset for California net operating losses was not more likely than not to be realized. As a result, we have established a valuation allowance on our net deferred tax assets for this amount. | |
The total amount of unrecognized tax benefits was approximately $88,000 as of March 31, 2014. The accrual for the unrecognized tax benefit relates to a tax liability for prior years and the current year in states where the Company has not previously filed offset by net benefit that will be received from filing amended returns in California. The Company is in the process of filing prior year and current year tax returns in these states under each state’s voluntary disclosure amnesty programs. The gross liability for income taxes related to unrecognized tax benefits is included in other current liabilities in the Company's balance sheet. There are no penalties or interest related to uncertain tax positions accrued as of March 31, 2014. | |
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the financial reporting basis and tax basis of our assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. | |
We are subject to taxation in the U.S., Switzerland, and various state jurisdictions. Our tax years for the fiscal year ended June 30, 2005 and forward are subject to examination by U.S. and state tax authorities and our tax years for the fiscal year ended June 30, 2007 and forward are subject to examination by the Switzerland tax authorities. | |
We do not record U.S. income tax expense for NAIE’s retained earnings that are declared as indefinitely reinvested offshore, thus reducing our overall income tax expense. The amount of earnings designated as indefinitely reinvested in NAIE is based on the actual deployment of such earnings in NAIE’s assets and our expectations of the future cash needs of our U.S. and foreign entities. Income tax laws are also a factor in determining the amount of foreign earnings to be indefinitely reinvested offshore. | |
It is our policy to establish reserves based on management’s assessment of exposure for certain positions taken in previously filed tax returns that may become payable upon audit by tax authorities. The tax reserves are analyzed quarterly and adjustments are made as events occur that we believe warrant adjustments to the reserves. |
Note_J_Treasury_Stock
Note J - Treasury Stock | 9 Months Ended |
Mar. 31, 2014 | |
Disclosure Text Block Supplement [Abstract] | ' |
Treasury Stock [Text Block] | ' |
J. Treasury Stock | |
On June 2, 2011, the Board of Directors authorized the repurchase of up to $2.0 million of our common stock. Under the repurchase plan, we may, from time to time, purchase shares of our common stock, depending upon market conditions, in open market or privately negotiated transactions. For the year ended June 30, 2013, we purchased 132,132 shares at a weighted average cost of $5.32 per share and a total cost of $703,000, including commissions and fees. During the three months ended March 31, 2014, we did not purchase any common stock as part of the repurchase plan. During the nine months ended March 31, 2014, we purchased 5,100 shares at a weighted average cost of $4.55 per share and a total cost of $23,000 including commissions and fees. | |
During the quarter ended March 31, 2014 we acquired 6,701 shares from employees in connection with restricted stock shares that vested during the quarter. These shares were returned to the Company by the related employees and in return the Company paid each employee’s required tax withholding. The valuation of the shares acquired and thereby the amount of shares returned to the Company was calculated based on the closing share price on the date the shares vested. |
Note_K_Derivatives_and_Hedging
Note K - Derivatives and Hedging | 9 Months Ended |
Mar. 31, 2014 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' |
Derivative Instruments and Hedging Activities Disclosure [Text Block] | ' |
K. Derivatives and Hedging | |
We are exposed to gains and losses resulting from fluctuations in foreign currency exchange rates relating to forecasted product sales denominated in foreign currencies and transactions of NAIE, our foreign subsidiary. As part of our overall strategy to manage the level of exposure to the risk of fluctuations in foreign currency exchange rates, we may use foreign exchange contracts in the form of forward contracts. There can be no guarantee any such contracts, to the extent we enter into such contracts, will be effective hedges against our foreign currency exchange risk. | |
During the three and nine months ended March 31, 2014, we had forward contracts designated as cash flow hedges primarily to protect against the foreign exchange risks inherent in our forecasted sales of products at prices denominated in currencies other than the U.S. Dollar. These contracts are expected to be settled through August 2015. For derivative instruments that are designated and qualify as cash flow hedges, we record the effective portion of the gain or loss on the derivative in accumulated other comprehensive income (“OCI”) as a separate component of stockholders’ equity and subsequently reclassify these amounts into earnings in the period during which the hedged transaction is recognized in earnings. | |
For foreign currency contracts designated as cash flow hedges, hedge effectiveness is measured using the spot rate. Changes in the spot-forward differential are excluded from the test of hedge effectiveness and are recorded currently in earnings as interest expense. We measure effectiveness by comparing the cumulative change in the hedge contract with the cumulative change in the hedged item. During the three and nine months ended March 31, 2014, we did not have any losses or gains related to the ineffective portion of our hedging instruments. No hedging relationships were terminated as a result of ineffective hedging or forecasted transactions no longer probable of occurring for foreign currency forward contracts. We monitor the probability of forecasted transactions as part of the hedge effectiveness testing on a quarterly basis. | |
As of March 31, 2014, the notional amounts of our foreign exchange contracts designated as cash flow hedges were approximately $14.2 million (EUR 10.4 million). As of March 31, 2014, a net loss of approximately $127,000 related to derivative instruments designated as cash flow hedges was recorded in OCI. We expect approximately $129,000 will be reclassified into earnings in the next 12 months along with the earnings effects of the related forecasted transactions. | |
As of March 31, 2014, the fair value of our cash flow hedges was a net liability of $204,000. Of this amount $11,000 was classified in prepaids and other current assets, $217,000 was classified in accrued liabilities, and $2,000 was classified as other noncurrent assets, net in our Condensed Consolidated Balance Sheets. During the three months ended March 31, 2014 we recognized $35,000 of gains in OCI and reclassified $116,000 of losses from OCI to revenue. During the nine months ended March 31, 2014 we recognized $533,000 of losses in OCI and reclassified $361,000 of losses from OCI to revenue. During the three months ended March 31, 2013 we recognized $217,000 of gains in OCI and reclassified 11,000 of gains from OCI to revenue. During the nine months ended March 31, 201 we recognized $167,000 of gains in OCI and reclassified $518,000 of gains from OCI to revenue. |
Note_L_Contingencies
Note L - Contingencies | 9 Months Ended |
Mar. 31, 2014 | |
Disclosure Text Block Supplement [Abstract] | ' |
Legal Matters and Contingencies [Text Block] | ' |
L. Contingencies | |
From time to time, we become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters may relate to product liability, employment, intellectual property, tax, regulation, contract or other matters. The resolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources. While unfavorable outcomes are possible, based on available information, we generally do not believe the resolution of these matters will result in a material adverse effect on our business, consolidated financial condition, or results of operation. However, a settlement payment or unfavorable outcome could adversely impact our results of operation. Our evaluation of the likely impact of these actions could change in the future and we could have unfavorable outcomes that we do not expect. | |
On September 8, 2011, NAI and CSI filed a complaint in the U.S. District Court for the District of Delaware against DNP International Co., Inc. (DNP) alleging claims of unfair competition, violation of the Delaware Deceptive Trade Practices Act and interference with business relations. On December 22, 2011, DNP filed a complaint in the U.S. District Court for the District of Delaware against NAI and CSI for declaratory judgment of non-infringement and invalidity of three of NAI’s patents. On January 27, 2012, DNP amended its complaint to add declaratory judgment claims against a fourth NAI patent (“381 patent). On February 6, 2012, the Company and CSI moved to dismiss the cases related to the three previously asserted patents for lack of subject matter jurisdiction. On the same day, the Company filed its answer and counterclaims for infringement by DNP of the “381 patent. DNP subsequently agreed to voluntarily dismiss CSI from the lawsuit. On March 2, 2012, the Court ordered the dismissal of CSI. On April 15, 2013, the Court consolidated the two lawsuits referenced above for purposes of pretrial matters. The Court also entered a Scheduling Order setting a trial date in April 2015. | |
On December 21, 2011, NAI filed a lawsuit in the U.S. District Court for the Southern District of Texas, Houston Division, alleging infringement by Woodbolt Distribution, LLC, also known as Cellucor (Woodbolt), Vitaquest International, Inc., d/b/a Garden State Nutritionals (Garden State) and F.H.G. Corporation, d/b/a Integrity Nutraceuticals (Integrity), of NAI’s ’381 patent. The complaint alleges that Woodbolt sells nutritional supplements, including supplements containing beta-alanine such as C4 Extreme™, M5 Extreme™, and N-Zero Extreme™, that infringe the “381 patent. Woodbolt, in turn, filed a complaint seeking a declaratory judgment of non-infringement and invalidity of the ’381 patent in the U.S. District Court for the District of Delaware. On February 17, 2012, Woodbolt filed a First Amended Complaint, realleging its original claims against the Company and asserting new claims of violation of the Sherman Antitrust Act (15 U.S.C. § 2) and Unfair Competition. The Company reasserted the arguments in its prior motion to dismiss and moved to dismiss the new claims asserted by Woodbolt. On January 23, 2013, the Delaware Court granted the Company’s motion to dismiss Woodbolt’s case. On June 5, 2012, the Court in the above-referenced Texas case consolidated the pending suit with a second patent infringement case filed against Woodbolt by the Company on May 3, 2012, asserting infringement its “422 patent. On November 9, 2012, NAI filed a supplemental complaint adding allegations of infringement of Woodbolt’s Cellucor Cor –Performance ß-BCAA™ and Cellucor Cor –Performance™ Creatine products. On June 14, 2013, NAI filed a third patent infringement lawsuit in the U.S. District Court for the Southern District of Texas, Houston Division, against Woodbolt, BodyBuilding.com and GNC Corporation alleging infringement of the “381 and “422 patents by Woodbolt’s Neon Sport Volt™ product. Woodbolt asserted the same defenses and counterclaims as set forth in the earlier lawsuits. On June 24, 2013, the Court consolidated the case with the earlier-filed lawsuits identified above. On June 25, 2013, Woodbolt filed a lawsuit in the U.S. District Court for the Southern District of Texas, Houston Division, against a newly-issued NAI U.S. patent no. 8,470,865, asserting declaratory judgment claims of non-infringement, invalidity and unenforceability. On July 1, 2013, Woodbolt’s lawsuit was consolidated with the three pending lawsuits filed by NAI. On July 24, 2013, NAI filed its Answer and Amended Counterclaims against Woodbolt alleging infringement of the “865 patent by the products accused in the pending cases previously filed by NAI. On August 14, 2013, Woodbolt filed a counterclaim to NAI’s counterclaim asserting violation of the Sherman Antitrust Act (15 U.S.C. § 2) and Unfair Competition. On September 4, 2013, NAI moved to have Woodbolt’s counterclaims dismissed from the case. All of the consolidated cases remain pending. Woodbolt has also requested inter partes re-examination of the ’381 and ’422 patents by the USPTO. On July 26, 2012, the USPTO accepted the request to re-examine the ’381 patent. On December 6, 2013, the USPTO rejected the claims of the “381 patent and issued a right of appeal notice. On January 6, 2014, the Company filed its notice of appeal. On August 17, 2012, the USPTO accepted the request to re-exam the ’422 patent. | |
A declaration of non-infringement, invalidity or unenforceability of certain of our patents could have a material adverse impact upon our business results, operations, and financial condition. | |
On February 13, 2013, several entities, including the Company, were sued for various causes of action pertaining to product liability in Superior Court for the State of California (County of San Diego) captioned Sparling v. USPLabs, LLC, et al. Case No. 37-2013-00034663-CU-PL-CTL. On March 21, 2013, co-defendant USP Labs LLC filed a Notice of Removal to the U.S. District Court for the Southern District of California, Civil Action No. 3:13-cv-00667-JLS-DHB. Specific allegations against the Company are for negligence, strict products liability, breach of express and implied warranties and wrongful death. The Company has been provided with defense counsel by CSI’s insurance company. Additionally, the Company has sought indemnification from co-defendant USPLabs, LLC. The Company is not involved in the formulation, manufacture, distribution or sale of the product at issue in the lawsuit. On April 19, 2013, the Company filed a motion to dismiss the allegations against it. On October 11, 2013, the Court granted a motion by co-defendant, USPLabs’, to transfer the case to the U.S. District Court for the Western District of Texas. The Court has set a trial date for March 26, 2015. The Company’s motion to dismiss is still pending. | |
On May 8, 2013, several entities, including the Company, were sued for various causes of action pertaining to product liability in Superior Court for the State of California (County of Los Angeles) captioned Carolyne v. USPLabs, LLC, Case No. BC 508212. Specific allegations against the Company are for negligence, strict products liability, breach of express and implied warranties. The Company has been provided with defense counsel by CSI’s insurance company. Additionally, the Company has sought indemnification from co-defendant USPLabs. The Company is not involved in the formulation, manufacture, distribution or sale of the product at issue in the lawsuit. On June 28, 2013, the Company filed a demurrer seeking dismissal of the allegations against it. The Company’s motion is still pending. | |
On November 1, 2013, several entities, including the Company, were sued for various causes of action pertaining to product liability in Superior Court for the State of California (County of San Diego) captioned Reed v. USPLabs, LLC, Case No. 37-2013-00074052. Specific allegations against the Company are for negligence, strict products liability, and breach of express and implied warranties. The Company has been provided with defense counsel by CSI’s insurance company. Additionally, the Company has sought indemnification from co-defendant USPLabs. The Company is not involved in the formulation, manufacture, distribution or sale of the product at issue in the lawsuit. The case has been removed to U.S. District Court for the Southern District of California. On December 27, 2013, the Company filed a motion to dismiss the allegations against it. The Company’s motion is still pending. | |
On November 1, 2013, several entities, including the Company, were sued for various causes of action pertaining to product liability in U.S. District Court for the Western District of Texas captioned Ogbonna v. USPLabs, LLC, Case No. 13-cv-340. While the Company is named in the caption, the complaint does not contain any specific allegations against the Company. The Company has been provided with defense counsel by CSI’s insurance company. Additionally, the Company has sought indemnification from co-defendant USPLabs. The Company is not involved in the formulation, manufacture, distribution or sale of the product at issue in the lawsuit. The case has been removed to U.S. District Court for the Southern District of California. On January 28, 2014, the Company filed a motion to dismiss the allegations against it. On February 19, 2014, the Company’s motion to dismiss was granted by the Court. | |
On January 24, 2014, several entities, including the Company, were sued for various causes of action pertaining to product liability in Superior Court for the State of California (County of Los Angeles) captioned Little v. USPLabs, LLC, Case No. BC534065. Specific allegations against the Company are for negligence, strict products liability, and breach of express and implied warranties. The Company has been provided with defense counsel by CSI’s insurance company. Additionally, the Company has sought indemnification from co-defendant USPLabs. The Company is not involved in the formulation, manufacture, distribution or sale of the product at issue in the lawsuit. The Company is not involved in the formulation, manufacture, distribution or sale of the product at issue in the lawsuit. On February 28, 2014, USPLabs filed a Notice of Removal from the Superior Court for the State of California to the U.S. District Court for the Central District of California. On March 7, 2014, the Company filed a Motion to Dismiss. On March 17, 2014, plaintiffs filed a Motion to Remand the case back to Superior Court. On April 25, 2014, the District Court granted plaintiffs’ Motion to Remand based on a lack of subject matter jurisdiction and therefore also denied the Company’s Motion to Dismiss as moot. The Company intends to file a Demurrer to dismiss the allegations against it in Superior Court. |
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 6 Months Ended | 9 Months Ended | ||||||||||||||||
Dec. 31, 2013 | Mar. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ' | ||||||||||||||||
Basis of Accounting, Policy [Policy Text Block] | ' | ' | ||||||||||||||||
Basis of Presentation | ||||||||||||||||||
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and applicable rules and regulations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. In management’s opinion, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows have been included and are of a normal, recurring nature. The results of operations for the three and nine months ended March 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future periods. | ||||||||||||||||||
You should read the financial statements and these notes, which are an integral part of the financial statements, together with our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2013 (“2013 Annual Report”). The accounting policies used to prepare the financial statements included in this report are the same as those described in the notes to the consolidated financial statements in our 2013 Annual Report unless otherwise noted below. | ||||||||||||||||||
Reclassification, Policy [Policy Text Block] | ' | ' | ||||||||||||||||
Reclassifications | ||||||||||||||||||
Certain items previously reported in our prior years’ condensed consolidated financial statements have been reclassified to conform with current year presentation. The reclassification relates to the classification of certain operating expenses from our NAIE operations previously classified as cost of goods sold, which are now being classified as part of selling, general & administrative expenses. This reclassification was made to reflect the change in operational activity of NAIE, which has historically been primarily a manufacturing specific operation but is now transitioning to perform additional selling and administrative functions. The reclassified amount relating to the three months ended March 31, 2013 totaled $85,000. The reclassified amount relating to the nine months ended March 31, 2013 totaled $343,000. This reclassification had no effect on previously reported total assets, stockholders’ equity, or net income. | ||||||||||||||||||
New Accounting Pronouncements, Policy [Policy Text Block] | ' | ' | ||||||||||||||||
Recent Accounting Pronouncements | ||||||||||||||||||
In July 2013, the Financial Accounting Standards Board (the “FASB”) issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This amendment to previous income tax guidance clarifies that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax benefit is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be netted with the deferred tax asset. These amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. We adopted Accounting Standard Update 2013-11 during our third quarter of fiscal 2014 and there was not significant impact to our consolidated financial statements as a result of our adoption of this amendment. | ||||||||||||||||||
Earnings Per Share, Policy [Policy Text Block] | ' | ' | ||||||||||||||||
Net Income per Common Share | ||||||||||||||||||
We compute net income per common share using the weighted average number of common shares outstanding during the period, and diluted net income per common share using the additional dilutive effect of all dilutive securities. The dilutive impact of stock options account for the additional weighted average shares of common stock outstanding for our diluted net income per common share computation. We calculated basic and diluted net income per common share as follows (in thousands, except share and per share data): | ||||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||||
March 31, | March 31, | |||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||
Numerator | ||||||||||||||||||
Net income | $ | 622 | $ | 178 | $ | 904 | $ | 977 | ||||||||||
Denominator | ||||||||||||||||||
Basic weighted average common shares outstanding | 6,819 | 6,841 | 6,818 | 6,883 | ||||||||||||||
Dilutive effect of stock options | 24 | 3 | 28 | 8 | ||||||||||||||
Diluted weighted average common shares outstanding | 6,843 | 6,844 | 6,846 | 6,891 | ||||||||||||||
Basic net income per common share | $ | 0.09 | $ | 0.03 | $ | 0.13 | $ | 0.14 | ||||||||||
Diluted net income per common share | $ | 0.09 | $ | 0.03 | $ | 0.13 | $ | 0.14 | ||||||||||
Shares related to stock options representing the right to acquire 280,019 shares of common stock for the three months ended March 31, 2014, and 303,929 shares for the nine months ended March 31, 2014, were excluded from the calculation of diluted net income per common share, as the effect of their inclusion would have been anti-dilutive. | ||||||||||||||||||
Shares related to stock options representing the right to acquire 390,000 shares of common stock for the three months ended March 31, 2013, and 457,800 shares for the nine months ended March 31, 2013, were excluded from the calculation of diluted net income per common share, as the effect of their inclusion would have been anti-dilutive. | ||||||||||||||||||
Revenue Recognition, Policy [Policy Text Block] | ' | ' | ||||||||||||||||
Revenue Recognition | ||||||||||||||||||
To recognize revenue, four basic criteria must be met: 1) there is evidence that an arrangement exists; 2) delivery has occurred; 3) the fee is fixed or determinable; and 4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the seller’s price to the buyer is substantially fixed or determinable at the date of sale; (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product; (3) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product; (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller; (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and (6) the amount of future returns can be reasonably estimated. We recognize revenue upon determination that all criteria for revenue recognition have been met. The criteria are usually met at the time title passes to the customer, which usually occurs upon shipment. Revenue from shipments where title passes upon delivery is deferred until the shipment has been delivered. | ||||||||||||||||||
We record reductions to gross revenue for estimated returns of private label contract manufacturing products and branded products. The estimated returns are based on the trailing six months of private label contract manufacturing gross sales and our historical experience for both private label contract manufacturing and branded product returns. However, the estimate for product returns does not reflect the impact of a potential large product recall resulting from product nonconformance or other factors as such events are not predictable nor is the related economic impact estimable. | ||||||||||||||||||
We followed the provisions of ASU No. 2009-13 for all multiple element agreements. Under this guidance, the delivered item(s) has value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. | ||||||||||||||||||
A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that a deliverable has standalone value from the undelivered items, the deliverable is identified as a separate unit of accounting and the amounts allocated to the deliverable are recognized upon the delivery of the deliverable, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the deliverable through the relative selling price allocation exceed the upfront fee, the amount recognized upon the delivery of the deliverable is limited to the upfront fee received. If facts and circumstances dictate that the deliverable does not have standalone value, the transaction price, including any upfront fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered and accepted. | ||||||||||||||||||
In addition, we enter into arrangements that provide for milestone payments upon contractually stated events. Under the Milestone Method, we recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: 1) The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, 2) The consideration relates solely to past performance, and 3) The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to us. | ||||||||||||||||||
We currently own certain U.S. patents, and each patent’s corresponding foreign patent applications. All of these patents and patent rights relate to the ingredient known as beta-alanine marketed and sold under the CarnoSyn® trade name. We have sold this ingredient to a customer and, since March 2009, we have had an agreement with Compound Solutions, Inc. (CSI) under which we have agreed to grant a license of certain of our patent rights to customers of CSI who purchase beta-alanine from CSI. Before October 1, 2011, we received a fee from CSI that varied based on the amount of net sales of beta-alanine sold by CSI less CSI’s costs and other agreed upon expenses. As of October 1, 2011, we receive a fee from CSI that varies based on the quantity of beta-alanine sold by CSI and the source of such beta-alanine. | ||||||||||||||||||
In June 2011, we entered into a license and supply agreement (Agreement) with Abbott Laboratories (Abbott) under which we agreed to grant an exclusive license to Abbott for the use of beta-alanine in certain medical foods and medical nutritionals. Under the terms of the agreement, Abbott paid an initial license fee of $300,000, an additional fee of $300,000 in January 2012, and upon achievement of certain milestones, an additional license fee of $150,000 was paid on October 3, 2012. The license and supply agreement provided Abbott with the right to terminate the agreement at any time up to March 31, 2012, at which time, if not terminated, Abbott was required to pay $4.3 million payable over six annual payments with the initial installment payment of $708,334 due March 31, 2012. We have determined that each of the milestone payments meets the definition of a milestone in accordance with the milestone method of revenue recognition. | ||||||||||||||||||
In February 2012 and June 2012, we amended the Agreement and extended Abbott’s termination rights initially through July 31, 2012 and then further through October 31, 2012 in exchange for two payments of $354,167 each by Abbott to NAI. Abbott made the first payment on March 13, 2012 and the second payment on July 12, 2012. In October 2012, the Agreement was amended for a third time. Unless earlier terminated by Abbott, the amendment requires Abbott to pay to NAI (i) upon earlier of achievement of certain milestones or December 1, 2012, additional license fees of $204,167; (ii) upon earlier of achievement of certain milestones or June 1, 2013, additional license fees of $204,167; (iii) upon earlier of achievement of certain milestones or July 1, 2013, additional license fees of $150,000; (iv) upon earlier of achievement of certain milestones or December 1, 2013, additional license fees of $150,000; and (v) approximately $2.8 million payable over four annual payments beginning on March 31, 2014. The payment noted in (i) was collected in December 2012, the payment noted in (ii) was collected in May 2013, the payment noted in (iii) was collected in July 2013 and the payment noted in (iv) was collected in January 2014. | ||||||||||||||||||
Effective November 27, 2013, citing further time and cost required to bring its anticipated product to market, Abbott exercised its right to terminate the Agreement. | ||||||||||||||||||
We recorded royalty and licensing income as a component of revenue in the amount of $1.1 million during the three months ended March 31, 2014 and $3.8 million during the nine months ended March 31, 2014. We recorded royalty and licensing income as a component of revenue in the amount of $1.0 million during the three months ended March 31, 2013 and $3.2 million during the nine months ended March 31, 2013. These royalty and licensing income amounts resulted in royalty expense paid to the original patent holders from whom NAI acquired its patents and patent rights. We recognized royalty expense as a component of cost of goods sold in the amount of $143,000 during the three months ended March 31, 2014 and $523,000 during the nine months ended March 31, 2014. We recognized royalty expense as a component of cost of goods sold in the amount of $133,000 during the three months ended March 31, 2013 and $426,000 during the nine months ended March 31, 2013. | ||||||||||||||||||
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | ' | ' | ||||||||||||||||
Stock-Based Compensation | ||||||||||||||||||
We have an omnibus incentive plan that was approved by our Board of Directors effective as of October 15, 2009 and approved by our stockholders at the Annual Meeting of Stockholders held on November 30, 2009. Under the plan, we may grant nonqualified and incentive stock options and other stock-based awards to employees, non-employee directors and consultants. Our prior equity incentive plan was terminated effective as of November 30, 2009. | ||||||||||||||||||
We estimate the fair value of stock option awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions. Black-Scholes uses assumptions related to volatility, the risk-free interest rate, the dividend yield (which we assume to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities used in the model are based mainly on the historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect in the period of grant. The expected life of stock option grants is derived from historical experience. | ||||||||||||||||||
During fiscal 2013 we granted a total of 98,000 restricted stock shares to the members of our Board of Directors and certain key members of our management team pursuant to our 2009 Omnibus Incentive plan. Each restricted share will vest over three years and these shares cannot be sold or otherwise transferred and the rights to receive dividends, if declared by our Board of Directors, are forfeitable until the shares become vested. During the three months ended September 30, 2013, 10,000 of these shares were forfeited due to the termination of employment of one of the grantees. On March 7, 2014 we granted 105,000 restricted stock shares to the members of our Board of Directors and certain key members of our management team pursuant to our 2009 Omnibus Incentive plan. These restricted stock grants will vest over three years and cannot be sold or otherwise transferred and the rights to receive dividends, if declared by our Board of Directors, are forfeitable until the shares become vested. | ||||||||||||||||||
Our net income included stock based compensation expense of approximately $46,000 for the three months ended March 31, 2014 and approximately $148,000 for the nine months ended March 31, 2014. Our net income included stock based compensation expense of approximately $52,000 for the three months ended March 31, 2013 and approximately $135,000 for the nine months ended March 31, 2013. | ||||||||||||||||||
Fair Value Measurement, Policy [Policy Text Block] | ' | ' | ||||||||||||||||
Fair Value of Financial Instruments | ||||||||||||||||||
Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We use a three-level hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available under the circumstances. | ||||||||||||||||||
The fair value hierarchy is broken down into three levels based on the source of inputs. In general, fair values determined by Level 1 inputs use quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. We classify cash, cash equivalents, and marketable securities balances as Level 1 assets. Fair values determined by Level 2 inputs are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable or can be corroborated, either directly or indirectly by observable market data. Level 3 inputs are unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. These include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. | ||||||||||||||||||
As of March 31, 2014 and June 30, 2013, we did not have any financial assets or liabilities classified as Level 1. We classify derivative forward exchange contracts as Level 2 assets. The fair value of our forward exchange contracts as of March 31, 2014 was a net liability of $204,000. The fair value of our forward exchange contracts as of June 30, 2013 was an asset of $95,000. As of March 31, 2014 and June 30, 2013, we did not have any financial assets or liabilities classified as Level 3. We did not transfer any assets between Levels 1, 2 and 3 during fiscal 2013 or the nine month period ended March 31, 2014. |
Note_A_Basis_of_Presentation_a1
Note A - Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | ' | ||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
March 31, | March 31, | ||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||
Numerator | |||||||||||||||||
Net income | $ | 622 | $ | 178 | $ | 904 | $ | 977 | |||||||||
Denominator | |||||||||||||||||
Basic weighted average common shares outstanding | 6,819 | 6,841 | 6,818 | 6,883 | |||||||||||||
Dilutive effect of stock options | 24 | 3 | 28 | 8 | |||||||||||||
Diluted weighted average common shares outstanding | 6,843 | 6,844 | 6,846 | 6,891 | |||||||||||||
Basic net income per common share | $ | 0.09 | $ | 0.03 | $ | 0.13 | $ | 0.14 | |||||||||
Diluted net income per common share | $ | 0.09 | $ | 0.03 | $ | 0.13 | $ | 0.14 |
Note_B_Inventories_Tables
Note B - Inventories (Tables) | 9 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Schedule of Inventory, Current [Table Text Block] | ' | ||||||||
March 31, | June 30, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 10,214 | $ | 6,516 | |||||
Work in progress | 3,376 | 1,576 | |||||||
Finished goods | 1,582 | 2,358 | |||||||
Reserves | (805 | ) | (415 | ) | |||||
$ | 14,367 | $ | 10,035 |
Note_C_Property_and_Equipment_
Note C - Property and Equipment (Tables) | 9 Months Ended | ||||||||||||
Mar. 31, 2014 | |||||||||||||
Property, Plant and Equipment [Abstract] | ' | ||||||||||||
Property, Plant and Equipment [Table Text Block] | ' | ||||||||||||
Depreciable | March 31, | June 30, | |||||||||||
Life In Years | 2014 | 2013 | |||||||||||
Land | N/A | $ | 393 | $ | 393 | ||||||||
Building and building improvements | 7 – 39 | 2,793 | 2,793 | ||||||||||
Machinery and equipment | 3 – 12 | 26,523 | 26,141 | ||||||||||
Office equipment and furniture | 3 – 5 | 3,206 | 3,030 | ||||||||||
Vehicles | 3 | 209 | 136 | ||||||||||
Leasehold improvements | 1 – 15 | 10,921 | 10,771 | ||||||||||
Total property and equipment | 44,045 | 43,264 | |||||||||||
Less: accumulated depreciation and amortization | (35,170 | ) | (34,059 | ) | |||||||||
Property and equipment, net | $ | 8,875 | $ | 9,205 |
Note_D_Other_Comprehensive_Los1
Note D - Other Comprehensive (Loss) Income (Tables) | 9 Months Ended | ||||||||||||
Mar. 31, 2014 | |||||||||||||
Disclosure Text Block [Abstract] | ' | ||||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | ' | ||||||||||||
Three Months Ended March 31, 2014 | |||||||||||||
Defined Benefit | Unrealized | Total | |||||||||||
Pension Plan | Losses on Cash | ||||||||||||
Flow Hedges | |||||||||||||
Balance as of December 31, 2013 | $ | (482 | ) | $ | (151 | ) | $ | (633 | ) | ||||
Other comprehensive loss before reclassifications | — | 35 | 35 | ||||||||||
Amounts reclassified from OCI | — | 112 | 112 | ||||||||||
Tax effect of OCI activity | (36 | ) | (64 | ) | (100 | ) | |||||||
Other comprehensive loss | (36 | ) | 83 | 47 | |||||||||
Balance as of March 31, 2014 | $ | (518 | ) | $ | (68 | ) | $ | (586 | ) | ||||
Nine Months Ended March 31, 2014 | |||||||||||||
Defined Benefit | Unrealized | Total | |||||||||||
Pension Plan | Losses on Cash | ||||||||||||
Flow Hedges | |||||||||||||
Balance as of June 30, 2013 | $ | (482 | ) | $ | 52 | $ | (430 | ) | |||||
Other comprehensive loss before reclassifications | — | (533 | ) | (533 | ) | ||||||||
Amounts reclassified from OCI | — | 343 | 343 | ||||||||||
Tax effect of OCI activity | (36 | ) | 70 | 34 | |||||||||
Other comprehensive loss | (36 | ) | (120 | ) | (156 | ) | |||||||
Balance as of March 31, 2014 | $ | (518 | ) | $ | (68 | ) | $ | (586 | ) |
Note_F_Defined_Benefit_Pension1
Note F - Defined Benefit Pension Plan (Tables) | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | ' | ||||||||||||||||
Schedule of Net Benefit Costs [Table Text Block] | ' | ||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
March 31, | March 31, | ||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||
Interest cost | $ | 22 | $ | 22 | $ | 66 | $ | 66 | |||||||||
Expected return on plan assets | (9 | ) | (3 | ) | (28 | ) | (8 | ) | |||||||||
Net periodic expense | $ | 13 | $ | 19 | $ | 38 | $ | 58 |
Note_G_Economic_Dependency_Tab
Note G - Economic Dependency (Tables) | 9 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||||||
Note G - Economic Dependency (Tables) [Line Items] | ' | ||||||||||||||||||||||||||||||||
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | ' | ||||||||||||||||||||||||||||||||
Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||||||||||
Net Sales by | % of Total | Net Sales by | % of Total | Net Sales by | % of Total | Net Sales by | % of Total | ||||||||||||||||||||||||||
Customer | Net Sales | Customer | Net Sales | Customer | Net Sales | Customer | Net Sales | ||||||||||||||||||||||||||
Customer 1 | $ | 6,321 | 36 | % | $ | 7,304 | 50 | % | $ | 16,849 | 35 | % | $ | 22,172 | 53 | % | |||||||||||||||||
Customer 2 | 2,823 | 16 | 2,455 | 17 | 8,484 | 18 | 7,072 | 17 | |||||||||||||||||||||||||
Customer 3 | 2,921 | 17 | 1,483 | 10 | 7,960 | 17 | (a) | (a) | |||||||||||||||||||||||||
$ | 12,065 | 69 | % | $ | 11,242 | 77 | % | $ | 33,293 | 70 | % | $ | 29,244 | 70 | % | ||||||||||||||||||
Suplier 1&2 [Member] | ' | ||||||||||||||||||||||||||||||||
Note G - Economic Dependency (Tables) [Line Items] | ' | ||||||||||||||||||||||||||||||||
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | ' | ||||||||||||||||||||||||||||||||
Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||||||||||
Raw Material | % of Total | Raw Material | % of Total | Raw Material | % of Total | Raw Material | % of Total | ||||||||||||||||||||||||||
Purchases by | Raw | Purchases by | Raw | Purchases by | Raw | Purchases by | Raw | ||||||||||||||||||||||||||
Supplier | Material | Supplier | Material | Supplier | Material | Supplier | Material | ||||||||||||||||||||||||||
Purchases | Purchases | Purchases | Purchases | ||||||||||||||||||||||||||||||
Supplier 1 | (a) | (a) | $ | 829,000 | 14 | % | (a) | (a) | (a) | (a) | |||||||||||||||||||||||
(a) | (a) | $ | 829,000 | 14 | % | (a) | (a) | (a) | (a) |
Note_H_Segment_Information_Tab
Note H - Segment Information (Tables) | 9 Months Ended | ||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||
Note H - Segment Information (Tables) [Line Items] | ' | ||||||||||||||||||||||||
Revenue from External Customers by Geographic Areas [Table Text Block] | ' | ||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||
United States | $ | 8,992 | $ | 9,485 | $ | 26,695 | $ | 27,288 | |||||||||||||||||
Markets outside the United States | 10,135 | 6,350 | 26,062 | 18,693 | |||||||||||||||||||||
Total net sales | $ | 19,127 | $ | 15,835 | $ | 52,757 | $ | 45,981 | |||||||||||||||||
Long-lived Assets by Geographic Areas [Table Text Block] | ' | ||||||||||||||||||||||||
Long-Lived Assets | Total Assets | Capital Expenditures | |||||||||||||||||||||||
Nine Months Ended | |||||||||||||||||||||||||
March 31, | June 30, | March 31, | June 30, | March 31, | March 31, | ||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||
United States | $ | 6,588 | $ | 6,728 | $ | 34,376 | $ | 32,450 | $ | 1869 | $ | 635 | |||||||||||||
Europe | 2,287 | 2,477 | 15,153 | 14,190 | 329 | 719 | |||||||||||||||||||
$ | 8,875 | $ | 9,205 | $ | 49,529 | $ | 46,640 | $ | 2,198 | $ | 1,354 | ||||||||||||||
Net Sales and Income From Operations [Member] | ' | ||||||||||||||||||||||||
Note H - Segment Information (Tables) [Line Items] | ' | ||||||||||||||||||||||||
Schedule of Segment Reporting Information, by Segment [Table Text Block] | ' | ||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||
Net Sales | |||||||||||||||||||||||||
Private label contract manufacturing | $ | 17,692 | $ | 14,505 | $ | 48,056 | $ | 41,773 | |||||||||||||||||
Patent and trademark licensing | 1,141 | 1,009 | 3,812 | 3,207 | |||||||||||||||||||||
Branded products | 294 | 321 | 889 | 1,001 | |||||||||||||||||||||
$ | 19,127 | $ | 15,835 | $ | 52,757 | $ | 45,981 | ||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||
Income from Operations | |||||||||||||||||||||||||
Private label contract manufacturing | $ | 1,717 | $ | 1,353 | $ | 3,434 | $ | 3,924 | |||||||||||||||||
Patent and trademark licensing | 570 | 337 | 1,500 | 654 | |||||||||||||||||||||
Branded products | 46 | 11 | 61 | 85 | |||||||||||||||||||||
Income from operations of reportable segments | 2,333 | 1,701 | 4,995 | 4,663 | |||||||||||||||||||||
Corporate expenses not allocated to segments | (1,165 | ) | (1,132 | ) | (3,473 | ) | (3,338 | ) | |||||||||||||||||
$ | 1,168 | $ | 569 | $ | 1,522 | $ | 1,325 | ||||||||||||||||||
Total Assets [Member] | ' | ||||||||||||||||||||||||
Note H - Segment Information (Tables) [Line Items] | ' | ||||||||||||||||||||||||
Schedule of Segment Reporting Information, by Segment [Table Text Block] | ' | ||||||||||||||||||||||||
March 31, | June 30, | ||||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||||
Total Assets | |||||||||||||||||||||||||
Private label contract manufacturing | $ | 48,180 | $ | 45,032 | |||||||||||||||||||||
Patent and trademark licensing | 1,141 | 1,388 | |||||||||||||||||||||||
Branded products | 208 | 220 | |||||||||||||||||||||||
$ | 49,529 | $ | 46,640 |
Note_A_Basis_of_Presentation_a2
Note A - Basis of Presentation and Summary of Significant Accounting Policies (Details) (USD $) | 0 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||
Oct. 03, 2012 | Jan. 31, 2012 | Jun. 30, 2011 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Jun. 30, 2013 | Mar. 13, 2012 | Mar. 13, 2012 | Mar. 31, 2014 | Jul. 31, 2013 | 31-May-13 | Dec. 31, 2012 | Jul. 31, 2012 | Feb. 29, 2012 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 07, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Jun. 30, 2013 | Mar. 31, 2014 | Jun. 30, 2013 | Mar. 31, 2014 | Jun. 30, 2013 | Mar. 31, 2014 | Jun. 30, 2013 | |
Prior To Amendment [Member] | installment [Member] | installment [Member] | Amendment [Member] | Amendment [Member] | Amendment [Member] | Amendment [Member] | Amendment [Member] | Amendment [Member] | Equity Option [Member] | Equity Option [Member] | Equity Option [Member] | Equity Option [Member] | Omnibus Stock Incentive Plan 2009 [Member] | Omnibus Stock Incentive Plan 2009 [Member] | Omnibus Stock Incentive Plan 2009 [Member] | Omnibus Stock Incentive Plan 2009 [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Inputs, Level 3 [Member] | Significant Observable Input Level 2 [Member] | Significant Observable Input Level 2 [Member] | |||||||||
Note A - Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Prior Period Reclassification Adjustment | ' | ' | ' | ' | $85,000 | ' | $343,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 280,019 | 390,000 | 303,929 | 457,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from License Fees Received | 150,000 | 300,000 | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | 150,000 | 204,167 | 204,167 | 354,167 | 354,167 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Additional License Fees Upon Achievement Of Certain Milestones | ' | ' | ' | ' | ' | ' | ' | ' | 4,300,000 | ' | ' | ' | ' | ' | ' | ' | 2,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number Of Installment Payments | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6 | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Additional License Fees Receivable Upon Achievement Of Certain Milestones | ' | ' | ' | ' | ' | ' | ' | ' | 708,334 | ' | ' | ' | ' | ' | ' | ' | 150,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Royalty And Licensing Revenue | ' | ' | ' | 1,100,000 | 1,000,000 | 3,800,000 | 3,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Royalty Expense | ' | ' | ' | 143,000 | 133,000 | 523,000 | 426,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 105,000 | ' | ' | 98,000 | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | '3 years | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation | ' | ' | ' | 46,000 | 52,000 | 148,000 | 135,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Net Asset (Liability) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | 0 | 0 | ' | ' |
Foreign Currency Contracts, Liability, Fair Value Disclosure | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 204,000 | ' |
Foreign Currency Contract, Asset, Fair Value Disclosure | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 95,000 |
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount | ' | ' | ' | 0 | ' | 0 | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount | ' | ' | ' | 0 | ' | 0 | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 | ' | ' | ' | ' | ' | 0 | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | ' | ' | ' | ' | ' | $0 | ' | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_A_Basis_of_Presentation_a3
Note A - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Calculation of Basic and Diluted Net Income Per Common Share (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 |
Numerator | ' | ' | ' | ' |
Net income (in Dollars) | $622 | $178 | $904 | $977 |
Denominator | ' | ' | ' | ' |
Basic weighted average common shares outstanding | 6,819,071 | 6,841,163 | 6,817,643 | 6,883,304 |
Dilutive effect of stock options | 24,000 | 3,000 | 28,000 | 8,000 |
Diluted weighted average common shares outstanding | 6,842,951 | 6,843,897 | 6,845,765 | 6,891,023 |
Basic net income per common share (in Dollars per share) | $0.09 | $0.03 | $0.13 | $0.14 |
Diluted net income per common share (in Dollars per share) | $0.09 | $0.03 | $0.13 | $0.14 |
Note_B_Inventories_Details_Sum
Note B - Inventories (Details) - Summary of Inventories, Net (USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
In Thousands, unless otherwise specified | ||
Summary of Inventories, Net [Abstract] | ' | ' |
Raw materials | $10,214 | $6,516 |
Work in progress | 3,376 | 1,576 |
Finished goods | 1,582 | 2,358 |
Reserves | -805 | -415 |
$14,367 | $10,035 |
Note_C_Property_and_Equipment_1
Note C - Property and Equipment (Details) - Property and Equipment (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Jun. 30, 2013 |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment | $44,045 | $43,264 |
Less: accumulated depreciation and amortization | -35,170 | -34,059 |
Property and equipment, net | 8,875 | 9,205 |
Land [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | ' | ' |
Property and equipment | 393 | 393 |
Building and Building Improvements [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment | 2,793 | 2,793 |
Building and Building Improvements [Member] | Minimum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '7 years | ' |
Building and Building Improvements [Member] | Maximum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '39 years | ' |
Machinery and Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment | 26,523 | 26,141 |
Machinery and Equipment [Member] | Minimum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '3 years | ' |
Machinery and Equipment [Member] | Maximum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '12 years | ' |
Furniture and Fixtures [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment | 3,206 | 3,030 |
Furniture and Fixtures [Member] | Minimum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '3 years | ' |
Furniture and Fixtures [Member] | Maximum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '5 years | ' |
Vehicles [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '3 years | ' |
Property and equipment | 209 | 136 |
Leasehold Improvements [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment | $10,921 | $10,771 |
Leasehold Improvements [Member] | Minimum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '1 year | ' |
Leasehold Improvements [Member] | Maximum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, depreciable life in years | '15 years | ' |
Note_D_Other_Comprehensive_Los2
Note D - Other Comprehensive (Loss) Income (Details) (Reclassification out of Accumulated Other Comprehensive Income [Member], USD $) | 3 Months Ended | 9 Months Ended |
Mar. 31, 2014 | Mar. 31, 2014 | |
Reclassification out of Accumulated Other Comprehensive Income [Member] | ' | ' |
Note D - Other Comprehensive (Loss) Income (Details) [Line Items] | ' | ' |
Revenues | $116,000 | $361,000 |
Other Income | $4,000 | $18,000 |
Note_D_Other_Comprehensive_Los3
Note D - Other Comprehensive (Loss) Income (Details) - Other Comprehensive (Loss) Income (USD $) | 3 Months Ended | 9 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2014 |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ' | ' |
Balance | ($633) | ($430) |
Other comprehensive loss before reclassifications | 35 | -533 |
Amounts reclassified from OCI | 112 | 343 |
Tax effect of OCI activity | -100 | 34 |
Other comprehensive loss | 47 | -156 |
Balance | -586 | -586 |
Accumulated Defined Benefit Plans Adjustment [Member] | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ' | ' |
Balance | -482 | -482 |
Tax effect of OCI activity | -36 | -36 |
Other comprehensive loss | -36 | -36 |
Balance | -518 | -518 |
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ' | ' |
Balance | -151 | 52 |
Other comprehensive loss before reclassifications | 35 | -533 |
Amounts reclassified from OCI | 112 | 343 |
Tax effect of OCI activity | -64 | 70 |
Other comprehensive loss | 83 | -120 |
Balance | ($68) | ($68) |
Note_E_Debt_Details
Note E - Debt (Details) | 9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | |||||||||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Feb. 19, 2007 | Feb. 19, 2007 | Mar. 31, 2014 | Sep. 22, 2006 | Sep. 22, 2006 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | |
USD ($) | USD ($) | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | Natural Alternatives International Europe Sa [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member] | Minimum [Member] | |
Current Account Loans [Member] | Fixed Loans [Member] | Fixed Loans [Member] | Amended Line of Credit Facility [Member] | Amended Line of Credit Facility [Member] | Amended Line of Credit Facility [Member] | USD ($) | CHF | |||||||
USD ($) | CHF | USD ($) | USD ($) | CHF | ||||||||||
Note E - Debt (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity | $5,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | $1,500,000 | 1,300,000 | ' | ' | ' |
Line of Credit Facility, Commitment Fee Amount | 12,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Amount Outstanding | 0 | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' |
Net Income Required In Future For Income Covenant | 750,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ratio of Indebtedness to Net Capital | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.25 | 1 |
Long-term Debt, Percentage Bearing Variable Interest, Amount | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Instrument, Basis Spread on Variable Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.75% | ' | ' |
Debt Instrument Basis Spread On Elected Fixed Rate Borrowing | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.50% | ' | ' |
Line Of Credit Facility Outstanding Daily Balance During Period | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
LineOfCreditCovenantNumber Of Consecutive Days That Outstanding Balance Must Be Zero | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '30 days |
Minimum Prepayment Amount Under Line Of Credit | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line Of Credit Facility Maximum Borrowing Capacity Annual Reduction | ' | ' | ' | ' | ' | ' | ' | ' | ' | 180,000 | 160,000 | ' | ' | ' |
Line Of Credit Facility Maximum Amount Outstanding After Reduction | ' | ' | ' | ' | ' | ' | 564,000 | 500,000 | ' | ' | ' | ' | ' | ' |
Debt Instrument, Term | ' | ' | ' | ' | ' | ' | ' | ' | '24 months | ' | ' | ' | ' | ' |
Debt Instrument, Interest Rate, Stated Percentage | ' | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Prepayment Penalty Rate | ' | ' | ' | 0.10% | 0.10% | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Pre Payment Penalty | ' | ' | ' | 1,127 | 1,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Current Borrowing Capacity | ' | $5,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_F_Defined_Benefit_Pension2
Note F - Defined Benefit Pension Plan (Details) | Mar. 31, 2014 |
Compensation and Retirement Disclosure [Abstract] | ' |
Number Of Years Compensation Used For Benefit Obligation Assumptions | '5 years |
Note_F_Defined_Benefit_Pension3
Note F - Defined Benefit Pension Plan (Details) - Components Included in Defined Benefit Pension Plan's Net Periodic Benefit Expense (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 |
Components Included in Defined Benefit Pension Plan's Net Periodic Benefit Expense [Abstract] | ' | ' | ' | ' |
Interest cost | $22 | $22 | $66 | $66 |
Expected return on plan assets | -9 | -3 | -28 | -8 |
Net periodic expense | $13 | $19 | $38 | $58 |
Note_G_Economic_Dependency_Det
Note G - Economic Dependency (Details) - Substantial Net Sales to Certain Customers (USD $) | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | ||
Concentration Risk [Line Items] | ' | ' | ' | ' | |
Net Sales by Customer | $19,127,000 | $15,835,000 | $52,757,000 | $45,981,000 | |
Customer 1 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | ' | ' | ' | ' | |
Concentration Risk [Line Items] | ' | ' | ' | ' | |
Net Sales by Customer | 6,321,000 | 7,304,000 | 16,849,000 | 22,172,000 | |
% of Total Net Sales | 36.00% | 50.00% | 35.00% | 53.00% | |
Customer 2 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | ' | ' | ' | ' | |
Concentration Risk [Line Items] | ' | ' | ' | ' | |
Net Sales by Customer | 2,823,000 | 2,455,000 | 8,484,000 | 7,072,000 | |
% of Total Net Sales | 16.00% | 17.00% | 18.00% | 17.00% | |
Customer 3 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | ' | ' | ' | ' | |
Concentration Risk [Line Items] | ' | ' | ' | ' | |
Net Sales by Customer | 2,921,000 | 1,483,000 | 7,960,000 | ' | [1] |
% of Total Net Sales | 17.00% | 10.00% | 17.00% | ' | [1] |
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | ' | ' | ' | ' | |
Concentration Risk [Line Items] | ' | ' | ' | ' | |
Net Sales by Customer | $12,065,000 | $11,242,000 | $33,293,000 | $29,244,000 | |
% of Total Net Sales | 69.00% | 77.00% | 70.00% | 70.00% | |
[1] | Sales were less than 10% of the respective period's total private label contract manufacturing net sales. |
Note_G_Economic_Dependency_Det1
Note G - Economic Dependency (Details) - Total Raw Material Purchases (USD $) | 3 Months Ended | 9 Months Ended | |||||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |||
Concentration Risk [Line Items] | ' | ' | ' | ' | |||
Raw Material Purchases by Supplier | ' | [1] | $829,000 | ' | [1] | ' | [1] |
% of Total Raw Material Purchase | ' | [1] | 14.00% | ' | [1] | ' | [1] |
Supplier 1 [Member] | ' | ' | ' | ' | |||
Concentration Risk [Line Items] | ' | ' | ' | ' | |||
Raw Material Purchases by Supplier | ' | [1] | $829,000 | ' | [1] | ' | [1] |
% of Total Raw Material Purchase | ' | [1] | 14.00% | ' | [1] | ' | [1] |
[1] | Purchases were less than 10% of the respective period's total raw material purchases. |
Note_H_Segment_Information_Det
Note H - Segment Information (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Note H - Segment Information (Details) [Line Items] | ' | ' | ' | ' |
Number of Reportable Segments | ' | ' | 3 | ' |
Revenue, Net (in Dollars) | $19,127,000 | $15,835,000 | $52,757,000 | $45,981,000 |
Natural Alternatives International Europe Sa [Member] | Geographic Concentration Risk [Member] | Markets Outside the United States [Member] | Sales Revenue, Net [Member] | ' | ' | ' | ' |
Note H - Segment Information (Details) [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | 61.00% | 73.00% | 55.00% | 72.00% |
Natural Alternatives International Europe Sa [Member] | ' | ' | ' | ' |
Note H - Segment Information (Details) [Line Items] | ' | ' | ' | ' |
Revenue, Net (in Dollars) | ' | ' | 0 | 0 |
Markets Outside the United States [Member] | ' | ' | ' | ' |
Note H - Segment Information (Details) [Line Items] | ' | ' | ' | ' |
Revenue, Net (in Dollars) | $10,135,000 | $6,350,000 | $26,062,000 | $18,693,000 |
Note_H_Segment_Information_Det1
Note H - Segment Information (Details) - Operating Results by Business Segment (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Net Sales | ' | ' | ' | ' |
Net Sales | $19,127,000 | $15,835,000 | $52,757,000 | $45,981,000 |
Income from Operations | ' | ' | ' | ' |
Income from Operations | 1,168,000 | 569,000 | 1,522,000 | 1,325,000 |
Private Label Contract Manufacturing [Member] | Operating Segments [Member] | ' | ' | ' | ' |
Income from Operations | ' | ' | ' | ' |
Income from Operations | 1,717,000 | 1,353,000 | 3,434,000 | 3,924,000 |
Private Label Contract Manufacturing [Member] | ' | ' | ' | ' |
Net Sales | ' | ' | ' | ' |
Net Sales | 17,692,000 | 14,505,000 | 48,056,000 | 41,773,000 |
Patent and Trademark Licensing [Member] | Operating Segments [Member] | ' | ' | ' | ' |
Income from Operations | ' | ' | ' | ' |
Income from Operations | 570,000 | 337,000 | 1,500,000 | 654,000 |
Patent and Trademark Licensing [Member] | ' | ' | ' | ' |
Net Sales | ' | ' | ' | ' |
Net Sales | 1,141,000 | 1,009,000 | 3,812,000 | 3,207,000 |
Branded Products [Member] | Operating Segments [Member] | ' | ' | ' | ' |
Income from Operations | ' | ' | ' | ' |
Income from Operations | 46,000 | 11,000 | 61,000 | 85,000 |
Branded Products [Member] | ' | ' | ' | ' |
Net Sales | ' | ' | ' | ' |
Net Sales | 294,000 | 321,000 | 889,000 | 1,001,000 |
Operating Segments [Member] | ' | ' | ' | ' |
Income from Operations | ' | ' | ' | ' |
Income from Operations | 2,333,000 | 1,701,000 | 4,995,000 | 4,663,000 |
Corporate, Non-Segment [Member] | ' | ' | ' | ' |
Income from Operations | ' | ' | ' | ' |
Income from Operations | ($1,165,000) | ($1,132,000) | ($3,473,000) | ($3,338,000) |
Note_H_Segment_Information_Det2
Note H - Segment Information (Details) - Operating Results by Business Segment (USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
In Thousands, unless otherwise specified | ||
Total Assets | ' | ' |
Total Assets | $49,529 | $46,640 |
Private Label Contract Manufacturing [Member] | ' | ' |
Total Assets | ' | ' |
Total Assets | 48,180 | 45,032 |
Patent and Trademark Licensing [Member] | ' | ' |
Total Assets | ' | ' |
Total Assets | 1,141 | 1,388 |
Branded Products [Member] | ' | ' |
Total Assets | ' | ' |
Total Assets | $208 | $220 |
Note_H_Segment_Information_Det3
Note H - Segment Information (Details) - Net Sales by Geographic Region (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Note H - Segment Information (Details) - Net Sales by Geographic Region [Line Items] | ' | ' | ' | ' |
Net sales | $19,127,000 | $15,835,000 | $52,757,000 | $45,981,000 |
United States [Member] | ' | ' | ' | ' |
Note H - Segment Information (Details) - Net Sales by Geographic Region [Line Items] | ' | ' | ' | ' |
Net sales | 8,992,000 | 9,485,000 | 26,695,000 | 27,288,000 |
Markets Outside the United States [Member] | ' | ' | ' | ' |
Note H - Segment Information (Details) - Net Sales by Geographic Region [Line Items] | ' | ' | ' | ' |
Net sales | $10,135,000 | $6,350,000 | $26,062,000 | $18,693,000 |
Note_H_Segment_Information_Det4
Note H - Segment Information (Details) - Assets and Capital Expenditures by Geographical Region (USD $) | 9 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Jun. 30, 2013 |
Note H - Segment Information (Details) - Assets and Capital Expenditures by Geographical Region [Line Items] | ' | ' | ' |
Long- Lived Assets | $8,875 | ' | $9,205 |
Total Assets | 49,529 | ' | 46,640 |
Capital Expenditures | 2,198 | 1,379 | ' |
UNITED STATES | ' | ' | ' |
Note H - Segment Information (Details) - Assets and Capital Expenditures by Geographical Region [Line Items] | ' | ' | ' |
Long- Lived Assets | 6,588 | ' | 6,728 |
Total Assets | 34,376 | ' | 32,450 |
Capital Expenditures | 1,869 | 635 | ' |
Europe [Member] | ' | ' | ' |
Note H - Segment Information (Details) - Assets and Capital Expenditures by Geographical Region [Line Items] | ' | ' | ' |
Long- Lived Assets | 2,287 | ' | 2,477 |
Total Assets | 15,153 | ' | 14,190 |
Capital Expenditures | $329 | $719 | ' |
Note_I_Income_Taxes_Details
Note I - Income Taxes (Details) (USD $) | 3 Months Ended | 9 Months Ended |
Mar. 31, 2014 | Mar. 31, 2014 | |
Income Tax Disclosure [Abstract] | ' | ' |
Effective Income Tax Rate Reconciliation, Percent | 40.90% | 37.20% |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | ' | 34.00% |
Deferred Tax Assets, Valuation Allowance | $193,000 | $193,000 |
Unrecognized Tax Benefits | 88,000 | 88,000 |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | $0 | $0 |
Note_J_Treasury_Stock_Details
Note J - Treasury Stock (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended |
Mar. 31, 2014 | Mar. 31, 2014 | Jun. 30, 2013 | Jun. 02, 2011 | |
Maximum [Member] | ||||
Note J - Treasury Stock (Details) [Line Items] | ' | ' | ' | ' |
Stock Repurchase Program, Authorized Amount (in Dollars) | ' | ' | ' | $2,000,000 |
Treasury Stock, Shares, Acquired | 0 | 5,100 | 132,132 | ' |
Treasury Stock Acquired, Average Cost Per Share (in Dollars per share) | ' | $4.55 | $5.32 | ' |
Treasury Stock, Value, Acquired, Cost Method (in Dollars) | ' | $23,000 | $703,000 | ' |
Shares Paid for Tax Withholding for Share Based Compensation | 6,701 | ' | ' | ' |
Note_K_Derivatives_and_Hedging1
Note K - Derivatives and Hedging (Details) | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||
Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | |
USD ($) | USD ($) | Scenario, Forecast [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Accounts Payable and Accrued Liabilities [Member] | Prepaid Expenses and Other Current Assets [Member] | Accrued Liabilities [Member] | Other Noncurrent Assets, Net [Member] | Cash Flow Hedging Foreign Exchange Contract [Member] | Cash Flow Hedging Foreign Exchange Contract [Member] | |
Reclassification out of Accumulated Other Comprehensive Income [Member] | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | EUR (€) | |||
USD ($) | |||||||||||||
Note K - Derivatives and Hedging (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net | $0 | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative, Notional Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14,200,000 | 10,400,000 |
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax | -127,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months | ' | ' | -129,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash Flow Hedge Derivative Instrument Liabilities at Fair Value | ' | ' | ' | ' | ' | ' | ' | 204,000 | ' | 217,000 | ' | ' | ' |
Cash Flow Hedge Derivative Instrument Assets at Fair Value | ' | ' | ' | ' | ' | ' | ' | ' | 11,000 | ' | 2,000 | ' | ' |
Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion | ' | ' | ' | 35,000 | 217,000 | ' | 167,000 | ' | ' | ' | ' | ' | ' |
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion | ' | ' | ' | 116,000 | ' | 361,000 | ' | ' | ' | ' | ' | ' | ' |
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion | ' | ' | ' | ' | ' | 533,000 | ' | ' | ' | ' | ' | ' | ' |
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion | ' | ' | ' | ' | $11,000 | ' | $518,000 | ' | ' | ' | ' | ' | ' |
Note_L_Contingencies_Details
Note L - Contingencies (Details) | Dec. 22, 2011 |
Disclosure Text Block Supplement [Abstract] | ' |
Number Of Patents In Lawsuit | 3 |